CD38-targeted therapies in kidney disease: evidence maturity, disease-stage dependence, and biomarker-guided retreatment.
- 1First School of Clinical Medicine, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.
- 2Department of Nephrology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an, Shaanxi, China.
Abstract
CD38 targeting can reach antibody-secreting cells that persist after B-cell depletion, along with selected natural killer-cell and other immune-cell subsets. This narrative review examines CD38-targeted antibodies in immune-mediated and monoclonal immunoglobulin-related kidney diseases and kidney transplantation. It asks what clinical studies establish, how disease stage may affect response durability, and whether biomarkers can guide retreatment. Evidence differs by agent, regimen, and outcome. The most mature randomized evidence with kidney-organ outcomes comes from daratumumab-based combination therapy in immunoglobulin light-chain (AL) amyloidosis, a plasma-cell disorder. In other kidney and transplant indications, early-phase randomized trials and uncontrolled studies show immunologic, tissue, or proteinuria responses, but long-term kidney or graft benefit remains unproven. Disease duration, previous treatment, and residual tissue injury may help explain variable responses, although treatment selection by disease stage has not been validated. Biomarkers measure distinct aspects of response and can support monitoring; changes alone do not establish pathogenic-cell depletion or justify retreatment. Biomarker-guided dosing was feasible in a selected transplant cohort and requires comparative validation. Clinical interpretation must remain specific to the studied antibody and regimen. Research priorities include trials with kidney and graft outcomes, prospective patient selection, comparisons of treatment strategies, validation of biomarker-guided retreatment, and cumulative safety during repeated therapy.
Related
- Direct randomized evidence for systemic targeted therapies in prurigo nodularis: a systematic review and meta-analysis
- Hippo pathway in cancer ferroptosis: from mechanism insights to targeted therapies
- Editorial: Targeted therapies in gastric cancer: molecular signatures and immune microenvironment insights
- Granulocyte-targeted therapies for airway diseases
- Targeted and Immune-Based Therapies in Cutaneous T-Cell Lymphomas
BibTeX
@article{feng2026cd38targeted,
title = {{CD38-targeted therapies in kidney disease: evidence maturity, disease-stage dependence, and biomarker-guided retreatment.}},
author = {Peidong Feng and Xiaoyong Yu},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1972506},
url = {https://europepmc.org/article/MED/42953460},
note = {CC BY},
}
RIS
TY - JOUR
TI - CD38-targeted therapies in kidney disease: evidence maturity, disease-stage dependence, and biomarker-guided retreatment.
AU - Peidong Feng
AU - Xiaoyong Yu
PY - 2026
DA - 2026/10/14
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1972506
UR - https://europepmc.org/article/MED/42953460
AB - CD38 targeting can reach antibody-secreting cells that persist after B-cell depletion, along with selected natural killer-cell and other immune-cell subsets. This narrative review examines CD38-targeted antibodies in immune-mediated and monoclonal immunoglobulin-related kidney diseases and kidney transplantation. It asks what clinical studies establish, how disease stage may affect response durability, and whether biomarkers can guide retreatment. Evidence differs by agent, regimen, and outcome. The most mature randomized evidence with kidney-organ outcomes comes from daratumumab-based combination therapy in immunoglobulin light-chain (AL) amyloidosis, a plasma-cell disorder. In other kidney and transplant indications, early-phase randomized trials and uncontrolled studies show immunologic, tissue, or proteinuria responses, but long-term kidney or graft benefit remains unproven. Disease duration, previous treatment, and residual tissue injury may help explain variable responses, although treatment selection by disease stage has not been validated. Biomarkers measure distinct aspects of response and can support monitoring; changes alone do not establish pathogenic-cell depletion or justify retreatment. Biomarker-guided dosing was feasible in a selected transplant cohort and requires comparative validation. Clinical interpretation must remain specific to the studied antibody and regimen. Research priorities include trials with kidney and graft outcomes, prospective patient selection, comparisons of treatment strategies, validation of biomarker-guided retreatment, and cumulative safety during repeated therapy.
SN - 2296-858X
ER -